Results 41 to 50 of about 693,247 (202)

Wild-Type Isocitrate Dehydrogenase-Dependent Oxidative Decarboxylation and Reductive Carboxylation in Cancer and Their Clinical Significance

, 2022
The human isocitrate dehydrogenase (IDH) gene encodes for the isoenzymes IDH1, 2, and 3, which catalyze the conversion of isocitrate and α-ketoglutarate (α-KG) and are required for normal mammalian metabolism. Isocitrate dehydrogenase 1 and 2
Junxiong Chen, Zijing Xie, Chen, Junxiong, Qiwei He, He, Qiwei, Zhenzhou Chen, Xie, Zijing, Chen, Zhenzhou   +7 more
core   +1 more source

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

Molecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler, Bilal A. Lone, Ecem Unal, A. Rouf Banday   +3 more
wiley   +1 more source

Isocitrate dehydrogenase 1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis

Open Medicine, 2022
The present study intends to clarify the hypothesis that isocitrate dehydrogenase 1 (IDH1) mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis through the in vitro and in vivo experiments.
Su Li, Huang Yi, Zheng Lei, Zhu Zhifa, Wu Yue, Li Ping   +5 more
doaj   +1 more source

Clinical Impact of MGMT Promoter Methylation in IDH‐Mutant Gliomas: Influence of Threshold Selection and Clinical Confounding

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background The clinical relevance of MGMT promoter methylation in IDH‐mutant gliomas remains controversial in the era of molecular classification. We aimed to systematically evaluate its clinical relevance by integrating quantitative assessment, cutoff exploration, and adjustment for clinical confounding.
Haihui Jiang, Linxi Cao, Xiaodong Chen, Siqi Tong, Qinghui Zhu, Jun Yang, Song Lin, Yong Cui   +7 more
wiley   +1 more source

Isocitrate Dehydrogenase (IDH) Mutations in Hematological Malignancies: Epidemiology, Mechanisms, and Therapeutic Strategies

MedComm – Future Medicine
Isocitrate dehydrogenase (IDH) mutation is an important molecular abnormality in hematological malignancies, occurring widely in various disease types such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (
Jinkun Xu, Haiying Bai, Lijuan Hu
doaj   +1 more source

Computational Analysis of , and Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas

Cancer Informatics, 2020
Introduction: The emergence of new omics approaches, such as genomic algorithms to identify tumor mutations and molecular modeling tools to predict the three-dimensional structure of proteins, has facilitated the understanding of the dynamic mechanisms ...
Mohammed Amine Bendahou, Housna Arrouchi, Wiame Lakhlili, Loubna Allam, Tarik Aanniz, Nadia Cherradi, Azeddine Ibrahimi, Mahjouba Boutarbouch   +7 more
doaj   +1 more source

Recent advances of IDH1 mutant inhibitor in cancer therapy

Frontiers in Pharmacology, 2022
Isocitrate dehydrogenase (IDH) is the key metabolic enzyme that catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG). Two main types of IDH1 and IDH2 are present in humans.
Wangqi Tian, Weitong Zhang, Yifan Wang, Ruyi Jin, Yuwei Wang, Hui Guo, Yuping Tang, Xiaojun Yao   +7 more
doaj   +1 more source

Immunohistochemistry as a tool for identifying PDGFRA amplification in central nervous system tumors. [PDF]

Brain Pathol
PDGFRA gene amplification is now recognized as a diagnostically and prognostically relevant molecular alteration in central nervous system tumors. Herein, we demonstrated that PDGFRA immunohistochemistry is a highly specific and sensitive biomarker for identifying PDGFRA amplification and should be part of the neuropathologist's routine panel of ...
Tauziède-Espariat A, Amargos G, Sassi F, Hasty L, Métais A, Varlet P.   +5 more
europepmc   +2 more sources

Isocitrate dehydrogenase from extremophiles; Molecular adaptations to high temperatures [PDF]

, 2006
Life on earth has adapted to a wide variety of environmental conditions, many of which are extreme to us humans. Temperature is one of the most important factors limiting biological activity and survival, but so far, biological activity has been observed
Stokke, Runar
core   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source